medigraphic.com
Instituto Nacional de Salud Pública

2021, Número 2

<< Anterior Siguiente >>

salud publica mex 2021; 63 (2)


Riesgos asociados con tabaquismo y posibles beneficios de cesación en Covid-19: una revisión narrativa rápida

Hernández-Pérez A, García-Gómez L, Rodríguez-Llamazares S, Thirión-Romero I, Osio-Echánove J, Pérez-Padilla R

Idioma: Ingles.
Referencias bibliográficas: 43
Paginas: 262-267
Archivo PDF: 246.30 Kb.


RESUMEN

Objetivo. Describir los posibles riesgos asociados de tabaquismo con contagio y complicaciones por Covid-19, haciendo hincapié en los beneficios de dejar de fumar. Material y métodos. Se utilizó la metodología de revisión narrativa y el proceso establecido para las revisiones rápidas Cochrane. Resultados. La evidencia científica relacionada con el tabaquismo y Covid-19 todavía es limitada. Existe una tendencia ya documentada en estudios clínicos transversales y metaanálisis del aumento del riesgo de resultados adversos para Covid-19 asociados con el consumo de tabaco. Conclusiones. Es necesario advertir que las personas que fuman tendrán mayores riesgos en la pandemia de Covid-19, los cuales se suman a los muchos ya conocidos del consumo de tabaco, de modo que dejar de fumar se convierte en una medida preventiva relevante para enfrentar mejor el SARS-CoV-2.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 [internet]. Geneva: WHO, 2020 [cited 2020 May 22]. Available from: https://www.who.int/dg/speeches/detail/ who-director-general-s-opening-remarks-at-the-media-briefing-on-covid- 19---11-march-2020

  2. World Health Organization. Coronavirus Disease (COVID-19) Dashboard [Internet]. Geneva: WHO, 2020 [cited 2020 Jul 1]. Available from: https://covid19.who.int

  3. The OpenSAFELY Collaborative, Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients [Internet]. MedRxiv. 2020 [cited 2020 May 27]. Available from: http://medrxiv.org/lookup/ doi/10.1101/2020.05.06.20092999

  4. Wang R, Pan M, Zhang X, Han M, Fan X, Zhao F, et al. Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. International Journal of Infectious Diseases. 2020;95:421-8. https://doi.org/10.1016/j.ijid.2020.03.070

  5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-62. https:// doi.org/10.1016/S0140-6736(20)30566-3

  6. World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco use 2000-2025, 3rd. ed. [Internet]. Geneva: WHO, 2019 [cited 2020 May 23]. Available from: https://www.who.int/ publications-detail/who-global-report-on-trends-in-prevalence-of-tobaccouse- 2000-2025-third-edition

  7. World Health Organization. WHO Global Report: Mortality Attributable to Tobacco [Internet]. Geneva: WHO, 2012 [cited 2020 May 23]. Available from: https://www.who.int/tobacco/publications/surveillance/ rep_mortality_attibutable/en/

  8. Garritty C, Gartlenhner G, Kamel C, Kiving VJ, Nussbaumer-Streit B, Stevens A, et al. Cochrane Rapid Reviers. Interim Guidance form the Cochrane Rapid Reviews Methods Group [Internet]. Cochrane Rapid Reviews Methods Group, 2020 [cited 2020 Jun 4]. Available from: https:// methods.cochrane.org/rapidreviews/sites/methods.cochrane.org.rapidreviews/ files/public/uploads/cochrane_rr_-_guidance-23mar2020-v1.pdf

  9. Berlin I, Thomas D, Le Faou A-L, Cornuz J. COVID-19 and Smoking. Nicotine & Tobacco Research. 2020;22(9):1650-2. https://doi.org/10.1093/ ntr/ntaa059

  10. Qiu F, Liang C-L, Liu H, Zeng YQ, Hou S, Huang S, et al. Impacts of cigarette smoking on immune responsiveness: Up and down or upside down? Oncotarget. 2017;8(1):268-84. https://doi.org/10.18632/oncotarget.13613

  11. Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. Inflammation Research. 2008;57(11):497-503. https://doi.org/10.1007/ s00011-008-8078-6

  12. van Zyl-Smit RN, Richards G, Leone FT. Tobacco smoking and COVID-19 infection. The Lancet Respiratory Medicine. 2020;8(7):664-5. https://doi.org/10.1016/S2213-2600(20)30239-3

  13. Eisenberg S-L, Eisenberg MJ. Smoking cessation during the COVID-19 Epidemic. Nicotine & Tobacco Research. 2020;22(9):1664-5. https://doi. org/10.1093/ntr/ntaa075

  14. Lawrence H, Hunter A, Murray R, Lim WS, McKeever T. Cigarette smoking and the occurrence of influenza – Systematic review. Journal of Infection. 2019;79(5):401-6. https://doi.org/10.1016/j.jinf.2019.08.014

  15. Olds JL, Kabbani N. Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population? Smoking and COVID19- infection. FEBS J. 2020;287(17):3651-5. https://doi.org/10.1111/febs.15303

  16. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett T-L, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55(5):1-5. https:// doi.org/10.1183/13993003.00688-2020

  17. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). JCM. 2020;9(3):841. https://doi.org/10.3390/jcm9030841

  18. World Health Organization. WHO statement: Tobacco use and COVID-19 [Internet]. WHO, 2020 [cited 2020 May 22]. Available from: https://www.who.int/news-room/detail/11-05-2020-who-statementtobacco- use-and-covid-19

  19. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75:1730-41. https://doi.org/10.1111/all.14238

  20. Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. 2020;8(4):20. https://doi.org/10.1016/ S2213-2600(20)30117-X

  21. Liu W, Tao Z-W, Wang L, Yuan M-L, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020;133(9):1032-8. https://doi. org/10.1097/CM9.0000000000000775

  22. Yu T, Cai S, Zheng Z, Cai X, Liu Y, Yin S, et al. Association between clinical manifestations and prognosis in patients with COVID-19. Clinical Therapeutics. 2020;42(6):964-972. https://doi.org/10.1016/j. clinthera.2020.04.009

  23. Vardavas C, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 2020;18:20. https://doi.org/10.18332/tid/119324

  24. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020;75:107-8. https://doi.org/10.1016/j.ejim.2020.03.014

  25. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and metaanalysis. Journal of Infection. 2020;81(2):16-25. https://doi.org/10.1016/j. jinf.2020.04.021

  26. Patanavanich R, Glantz SA. Smoking is Associated with COVID-19 Progression: a meta-analysis. Nicotine & Tobacco Research. 2020;22(9):1653-6. https://doi.org/10.1093/ntr/ntaa082

  27. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. Bhatt GC, ed. PLoS ONE. 2020;15(5):e0233147.

  28. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: A systematic review and meta-analysis. J Med Virol. 2020;92:1915-21. https://doi. org/10.1002/jmv.25889

  29. Leung JM, Yang CX, Sin DD. Reply to: “Current Smoking is Not Associated with COVID-19.” Eur Respir J. 2020;2001340 [cited 2020 May 23]. Available from: https://erj.ersjournals.com/content/erj/early/ 2020/04/29/13993003.01340-2020.full.pdf

  30. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):1-14. https://doi.org/10.1183/13993003.00547-2020

  31. Wong J, Lam DP, Abrishami A, Chan MTV, Chung F. Short-term preoperative smoking cessation and postoperative complications: a systematic review and meta-analysis. Can J Anaesth. 2012;59(3):268-79. https://doi. org/10.1007/s12630-011-9652-x

  32. Willemse BWM, Postma DS, Timens W, ten Hacken NHT. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J. 2004;23(3):464-76. https://doi.org/10.1183/09031936.04.00012704

  33. U.S. Department of Health and Human Services. Smoking Cessation: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2020. [cited 2020 May 23]. Available from: https:// www.hhs.gov/sites/default/files/2020-cessation-sgr-full-report.pdf

  34. King CC, Piper ME, Gepner AD, Fiore MC, Baker TB, Stein JH. The Longitudinal Impact of Smoking and Smoking Cessation on Inflammatory Markers of Cardiovascular Disease Risk. Arterioscler Thromb Vasc Biol. 2017;37(2):374-9. https://doi.org/10.1161/ATVBAHA.116.308728

  35. Hoyos A de, Southard C, DeCamp MM. Perioperative Smoking Cessation. Thoracic Surgery Clinics. 2012;22(1):1-12. https://doi.org/10.1016/j. thorsurg.2011.09.006

  36. World Health Organization. Fact sheet about health benefits of smoking cessation [Internet]. Geneva: WHO, 2020 [cited 2020 May 23]. Available from: https://www.who.int/tobacco/quitting/benefits/en/

  37. Patwardhan P. COVID-19: Risk of increase in smoking rates among England’s 6 million smokers and relapse among England’s 11 million ex-smokers. BJGP Open. 2020;4(2):bjgpopen20X101067. https://doi. org/10.3399/bjgpopen20X101067

  38. Hitchman SC, Fong GT, Zanna MP, Thrasher JF, Laux FL. The relation between number of smoking friends, and quit intentions, attempts, and success: findings from the International Tobacco Control (ITC) Four Country Survey. Psychol Addict Behav. 2014;28(4):1144-52. https://doi. org/10.1037/a0036483

  39. Chaiton MO, Mecredy G, Cohen J. Tobacco retail availability and risk of relapse among smokers who make a quit attempt: a population-based cohort study. Tobacco Control. 2018;27(2):163-9. https://doi.org/10.1136/ tobaccocontrol-2016-053490

  40. García-Gómez L, Hernández-Pérez A, Noé-Díaz V, Riesco-Miranda JA, Jiménez-Ruiz C. Smoking cessation treatments: current psychological and pharmacological options. RIC. 2019;71(1):1408. https://doi.org/10.24875/ RIC.18002629

  41. Klemperer EM, West JC, Peasley-Miklus C, Villanti AC. Change in tobacco and electronic cigarette use and motivation to quit in response to COVID-19. Nicotine Tob Res. 2020;22(9):1662-3. https://doi.org/10.1093/ ntr/ntaa072

  42. van Zyl-Smit RN, Richards G, Leone FT. Tobacco smoking and COVID-19 infection. The Lancet Respiratory Medicine. 2020;8(7):664-5. https://doi.org/10.1016/S2213-2600(20)30239-3

  43. World Health Organization. WHO Framework Convention on Tobacco Control. Geneva: World Health Organization, 2005 [cited 2020 May 23]. Available from: https://apps.who.int/iris/bitstream/handle/ 10665/42811/9241591013.pdf?sequence=1




2020     |     www.medigraphic.com